https://rch4.org/
progression is slowed by 65%
Cost: There is no cost. They provide this ALS drug free of charge as a humanitarian imperative.
Amylyx Pharmaceuticals.Centaur
With a typical survival time of between 2 to 5 years, people with ALS cannot wait, are now calling on the FDA to speed up the drug’s approval. The new ALS treatment is a combination of two drugs: a supplement (taurursodiol) and a medication used to treat a pediatric urea disorder (sodium phenylbutyrate).
https://www.amylyx.com/patients-caregivers/#centaur
ref - https://www.freethink.com/health/als-treatment
24/11/2019 - clinical trial - AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) (CENTAUR)
https://clinicaltrials.gov/ct2/show/NCT03127514
12/05/2021 - Global Phase 3 Trial of AMX0035 to Enroll 600 ALS Patients
Amylyx Pharmaceuticals Presents Trial Design of Global Phase 3 PHOENIX Study of AMX0035 in ALS at the European Network to Cure ALS (ENCALS) Meeting 2021
ref - https://alsnewstoday.com/news-posts/2021/05/14/amylyx-amx0035-phase-3-trial-details/
#als
progression is slowed by 65%
Cost: There is no cost. They provide this ALS drug free of charge as a humanitarian imperative.
Amylyx Pharmaceuticals.Centaur
With a typical survival time of between 2 to 5 years, people with ALS cannot wait, are now calling on the FDA to speed up the drug’s approval. The new ALS treatment is a combination of two drugs: a supplement (taurursodiol) and a medication used to treat a pediatric urea disorder (sodium phenylbutyrate).
https://www.amylyx.com/patients-caregivers/#centaur
ref - https://www.freethink.com/health/als-treatment
24/11/2019 - clinical trial - AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) (CENTAUR)
https://clinicaltrials.gov/ct2/show/NCT03127514
12/05/2021 - Global Phase 3 Trial of AMX0035 to Enroll 600 ALS Patients
Amylyx Pharmaceuticals Presents Trial Design of Global Phase 3 PHOENIX Study of AMX0035 in ALS at the European Network to Cure ALS (ENCALS) Meeting 2021
ref - https://alsnewstoday.com/news-posts/2021/05/14/amylyx-amx0035-phase-3-trial-details/
#als